Share on StockTwits

Illumina (NASDAQ:ILMN) VP Michel Bouchard sold 686 shares of the company’s stock on the open market in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $180.07, for a total transaction of $123,528.02. Following the completion of the transaction, the vice president now directly owns 24,190 shares in the company, valued at approximately $4,355,893. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Illumina (NASDAQ:ILMN) traded down 1.08% during mid-day trading on Wednesday, hitting $177.78. The stock had a trading volume of 1,178,291 shares. Illumina has a 52 week low of $72.77 and a 52 week high of $185.00. The stock has a 50-day moving average of $170.1 and a 200-day moving average of $161.7. The company has a market cap of $24.782 billion and a P/E ratio of 120.06.

Illumina (NASDAQ:ILMN) last announced its earnings results on Wednesday, July 23rd. The company reported $0.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.50 by $0.07. The company had revenue of $448.00 million for the quarter, compared to the consensus estimate of $426.50 million. During the same quarter last year, the company posted $0.43 earnings per share. Illumina’s revenue was up 29.5% compared to the same quarter last year. On average, analysts predict that Illumina will post $2.29 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Wedbush upgraded shares of Illumina from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 20th. They now have a $200.00 price target on the stock, up previously from $165.00. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Illumina in a research note on Monday, August 11th. They set a “buy” rating and a $200.00 price target on the stock. Finally, analysts at Goldman Sachs raised their price target on shares of Illumina from $184.00 to $187.00 in a research note on Tuesday, August 5th. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $178.92.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.